DuPont(US:DD)2026-02-10 14:00Financial Data and Key Metrics Changes - The company reported full year organic sales growth of 2%, operating EBITDA growth of 6%, and a 100 basis points margin expansion, leading to an adjusted EPS of $1.68 per share, up 16% year-over-year [4][11] - Fourth quarter net sales were $1.7 billion, flat compared to the previous year, with a 1% organic sales decline offset by a 1% benefit from currency [13] - Operating EBITDA for the fourth quarter was $409 million, a 4% increase year-over-year, with an operating EBITDA margin of 24.2%, up 80 basis points [14] Business Line Data and Key Metrics Changes - In the healthcare and water technologies segment, fourth quarter net sales were $821 million, up 4% year-over-year, driven by 3% organic growth [15] - The diversified industrials segment saw fourth quarter net sales of $872 million, a 3% decrease year-over-year, with a 4% organic decline [16] - Organic sales for healthcare and water technologies grew 5% in the second half of 2025, while diversified industrials experienced a 1% decline [14][19] Market Data and Key Metrics Changes - Organic growth in Europe was up 2% year-over-year, while Asia-Pacific saw a 2% decline, and North America was flat year-over-year [14] - The company expects mid-single-digit growth in healthcare and water technologies for 2026, while diversified industrials are projected to grow in the low single digits [19] Company Strategy and Development Direction - The company aims to drive above-market organic growth, build a robust business system, and deploy a balanced capital allocation model while consistently delivering financial results [6][10] - The strategic priorities for 2026 include enhancing core values, focusing on growth and continuous improvement, and maintaining a streamlined portfolio aligned with secular end markets [5][6] - The company plans to continue investing in innovation, having launched over 125 new products in 2025, generating more than $2 billion in sales [7][19] Management's Comments on Operating Environment and Future Outlook - Management noted a mixed macro environment, with expectations for mid-single-digit growth in healthcare and water technologies, flat overall automotive demand, and stabilization in construction markets [11][12] - The company is off to a good start in 2026, with January sales in line with expectations and improving order trends in industrial technologies [12] Other Important Information - The company completed a $500 million accelerated share repurchase (ASR) in Q4 2025 and has a $2 billion share repurchase authorization [10] - The company expects free cash flow generation to exceed 90% in 2026 [11] Q&A Session Summary Question: Can you provide more color on the industrial side and order trends? - Management indicated that industrial orders are picking up, particularly in aerospace, with low double-digit improvements in orders [28] Question: What is the outlook for the shelter business? - The shelter business is expected to start slightly down but improve throughout the year, leading to flat performance overall [39] Question: Can you discuss the Vitality Index and its impact? - The Vitality Index is at 30%, contributing positively to both top-line and margin growth, with new products showing higher margins than the overall company average [40][73] Question: What are the expectations for healthcare and water growth? - Management expects mid-single-digit growth in healthcare and water technologies, driven by demand in medical packaging and industrial water markets [19][83] Question: How will capital be allocated post-Aramids divestiture? - The company plans to remain shareholder-friendly, looking at both M&A opportunities and share repurchases without earmarking specific amounts for either [85][87]